UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 272

Sortiert nach

ABCL-719 Statewide Burden and Trend of Burkitt Lymphoma in the United States From 1990-2021: A Benchmarking Systematic Analysis for the Global Burden of Disease Study 2021

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S491-S492

2024

Volltextzugriff (PDF)

ABCL-340 Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase 2 Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S473-S473

2024

Volltextzugriff (PDF)

Managing Burkitt Lymphoma

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S124-S126

Crombie, Jennifer L.

2024

Volltextzugriff (PDF)

TCL-246 Peripheral T-Cell Lymphoma (PTCL) and treatment out-come Single centre retrospective study

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S522-S522

2024

Volltextzugriff (PDF)

Childhood and Adolescent Relapsed/Refractory Aggressive B-Cell Lymphomas With t(8;14) and BCL2 Expression, Burkitt Lymphoma Versus Diffuse Large B-Cell Lymphoma: A Diagnostic Challenge

Pediatric and developmental pathology, 2024-07, Vol.27 (4), p.348-353

2024

Volltextzugriff (PDF)

Tumor flare reaction in a patient with mycosis fungoides treated with a novel immune-epigenetic doublet

JAAD Case Reports, 2024-06, Vol.48, p.18-22

2024

Volltextzugriff (PDF)

Pattern of Bone Marrow Involvement in B-cell Non-Hodgkin’s Lymphoma - Experience from a Tertiary Care Center in North India

Journal of radiation and cancer research, 2024-05, Vol.15 (2), p.64-68

2024

Volltextzugriff (PDF)

Analysis of hepatitis B virus infection in 1424 patients with different pathological types of lymphoma (2018–2022): A real‐world, retrospective study

Cancer medicine (Malden, MA), 2024-05, Vol.13 (10), p.e7284-n/a

2024

Volltextzugriff (PDF)

Baseline immunoglobulin G and immune function in non-Hodgkin lymphoma: a retrospective analysis

Frontiers in immunology, 2024-04, Vol.15, p.1334899-1334899

2024

Volltextzugriff (PDF)

Hematological Complications of Human Immunodeficiency Virus (HIV) Infection: An Update From an HIV-Endemic Setting

Open forum infectious diseases, 2024-04, Vol.11 (4), p.ofae162-ofae162

2024

Volltextzugriff (PDF)

Copy Number Analysis of 9p24.1 in Classic Hodgkin Lymphoma Arising in Immune Deficiency/Dysregulation

Cancers, 2024-04, Vol.16 (7), p.1298

2024

Volltextzugriff (PDF)

Effect and Safety of Orelabrutinib and Lenalidomide Plus R-mini CDOP in Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Turkish journal of haematology, 2023-12, Vol.40 (4), p.284-285

2023

Volltextzugriff (PDF)

The pathobiology of select adolescent young adult lymphomas

EJHaem, 2023-11, Vol.4 (4), p.892-901

2023

Volltextzugriff (PDF)

Possible Concomitant Aggressive NK Cell Leukemia and EBV-positive T-cell lymphoma; Using the online beta version of WHO-HAEM5 and videoconferencing software to make diagnoses accessible in an emerging economy

Diagnostic pathology, 2023-10, Vol.18 (1), p.1-111, Article 111

2023

Volltextzugriff (PDF)

ABCL-515 Updated Results of the Safety Run-In of the Phase 3 LOTIS-5 Trial: Novel Combination of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCL

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S439-S440

2023

Volltextzugriff (PDF)

EXABS-140-LYM High Grade B-Cell Lymphoma: Pathologic Classification and Treatment Recommendations

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S54-S56

2023

Volltextzugriff (PDF)

Editorial: The molecular landscape and promising therapeutic targets in aggressive B-cell non-Hodgkin lymphomas

Frontiers in oncology, 2023-08, Vol.13, p.1278169

2023

Volltextzugriff (PDF)

Mediastinal Desmoid Tumor Presents as Lymphadenopathy in Patient with Lymphoma: A Case Report

Case reports in oncology, 2023-08, Vol.16 (1), p.765-770

2023

Volltextzugriff (PDF)

Safety of loncastuximab tesirine‐lpyl in diffuse large B‐cell lymphoma with severe hepatic dysfunction

Cancer, 2023-08, Vol.129 (15), p.2279-2283

2023

Volltextzugriff (PDF)

Long non‐coding RNA as a novel biomarker and therapeutic target in aggressive B‐cell non‐Hodgkin lymphoma: A systematic review

Journal of cellular and molecular medicine, 2023-07, Vol.27 (14), p.1928-1946

2023

Volltextzugriff (PDF)

Advanced penile lymphoma: Case report and review of the literature

Journal of cancer research and therapeutics, 2023-07, Vol.19 (3), p.823-825

2023

Volltextzugriff (PDF)

Systemic relapses of primary CNS lymphomas (PCNSL): a LOC network study

Annals of hematology, 2023-05, Vol.102 (5), p.1159-1169

2023

Volltextzugriff (PDF)

The SYK inhibitor: a novel agent for improved outcomes in relapsed/refractory diffuse large B-cell lymphoma

Future oncology (London, England), 2023-04, Vol.19 (11), p.737-738

2023

Volltextzugriff (PDF)

The new German evidence-based guideline on diffuse large B-cell lymphoma—key aspects for radiation oncologists

Strahlentherapie und Onkologie, 2023-02, Vol.199 (2), p.115-120

2023

Volltextzugriff (PDF)

Phase I study of novel SYK inhibitor TAK‐659 (mivavotinib) in combination with R‐CHOP for front‐line treatment of high‐risk diffuse large B‐cell lymphoma

EJHaem, 2023-02, Vol.4 (1), p.108-114

2023

Volltextzugriff (PDF)

1 – 25 von 272

Suche als RSS-Feed

Aktive Filter

KollektionEZB-NALI5-00465 Elsevier Archive NL

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(252)
Mit Volltextzugriff
(236)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(226)
Life Sciences & Biomedicine
(225)
Humans
(210)
Male
(152)
Female
(146)
Oncology
(136)
Middle Aged
(135)
Hematology
(129)
Adult
(125)
Aged
(114)
Lymphoma, Non-Hodgkin - Drug Therapy
(108)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(100)
Biological And Medical Sciences
(79)
Medical Sciences
(78)
Treatment Outcome
(78)
Adolescent
(66)
Prognosis
(66)
Cyclophosphamide - Administration & Dosage
(64)
Aggressive Lymphoma
(61)
Lymphoma, Non-Hodgkin - Pathology
(60)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

ABCL-719 Statewide Burden and Trend of Burkitt Lymphoma in the United States From 1990-2021: A Benchmarking Systematic Analysis for the Global Burden of Disease Study 2021

ABCL-340 Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase 2 Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume

Managing Burkitt Lymphoma

TCL-246 Peripheral T-Cell Lymphoma (PTCL) and treatment out-come Single centre retrospective study

Childhood and Adolescent Relapsed/Refractory Aggressive B-Cell Lymphomas With t(8;14) and BCL2 Expression, Burkitt Lymphoma Versus Diffuse Large B-Cell Lymphoma: A Diagnostic Challenge

Tumor flare reaction in a patient with mycosis fungoides treated with a novel immune-epigenetic doublet

Pattern of Bone Marrow Involvement in B-cell Non-Hodgkin’s Lymphoma - Experience from a Tertiary Care Center in North India

Analysis of hepatitis B virus infection in 1424 patients with different pathological types of lymphoma (2018–2022): A real‐world, retrospective study

Baseline immunoglobulin G and immune function in non-Hodgkin lymphoma: a retrospective analysis

Hematological Complications of Human Immunodeficiency Virus (HIV) Infection: An Update From an HIV-Endemic Setting

Copy Number Analysis of 9p24.1 in Classic Hodgkin Lymphoma Arising in Immune Deficiency/Dysregulation

Effect and Safety of Orelabrutinib and Lenalidomide Plus R-mini CDOP in Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma

The pathobiology of select adolescent young adult lymphomas

Possible Concomitant Aggressive NK Cell Leukemia and EBV-positive T-cell lymphoma; Using the online beta version of WHO-HAEM5 and videoconferencing software to make diagnoses accessible in an emerging economy

ABCL-515 Updated Results of the Safety Run-In of the Phase 3 LOTIS-5 Trial: Novel Combination of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCL

EXABS-140-LYM High Grade B-Cell Lymphoma: Pathologic Classification and Treatment Recommendations

Editorial: The molecular landscape and promising therapeutic targets in aggressive B-cell non-Hodgkin lymphomas

Mediastinal Desmoid Tumor Presents as Lymphadenopathy in Patient with Lymphoma: A Case Report

Safety of loncastuximab tesirine‐lpyl in diffuse large B‐cell lymphoma with severe hepatic dysfunction

Long non‐coding RNA as a novel biomarker and therapeutic target in aggressive B‐cell non‐Hodgkin lymphoma: A systematic review

Advanced penile lymphoma: Case report and review of the literature

Systemic relapses of primary CNS lymphomas (PCNSL): a LOC network study

The SYK inhibitor: a novel agent for improved outcomes in relapsed/refractory diffuse large B-cell lymphoma

The new German evidence-based guideline on diffuse large B-cell lymphoma—key aspects for radiation oncologists

Phase I study of novel SYK inhibitor TAK‐659 (mivavotinib) in combination with R‐CHOP for front‐line treatment of high‐risk diffuse large B‐cell lymphoma

Aktive Filter

Suchergebnisse filtern